The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 15, 2022. Its latest SEC filing is a 15-12G from Oct 31, 2022.
10-Q for Q2 FY2022, filed Aug 15, 2022
The sections below describe the company as of the FY2021 annual report.
Develops biology-based products for agriculture, packaging, healthcare, and other industries. Offers lab automation technology to organizations seeking to improve laboratory operations.
10-K for FY2021, filed Mar 30, 2022We partner with Nature to design, develop and commercialize microbes, molecules, and materials for diverse end markets. Our goal is to…View ↗
1.Advanced Materials. Our advanced materials business seeks to employ bio-advantaged molecules or microbes to develop and deliver high…View ↗
3.Automation. Our automation business offers proven automation technology to organizations interested in improving the throughput…View ↗
Customers pay for research and development work, usually through fixed fees across several phases and quarterly payments as work progresses. Some contracts add bonuses or milestone payments when results are accepted, or royalties tied to related sales.
10-K for FY2021, filed Mar 30, 2022The Company primarily earns revenue by engaging in R&D service contracts to help its customers improve the economics of their bio-based…View ↗
Performance bonuses, milestone payments and value share payments are the most common type of variable consideration. Performance bonuses…View ↗
The Company recognizes revenue over time or at a point in time. Substantially all of the Company's revenue related to current research and…View ↗
$16.7M
10-K for FY2021, filed Mar 30, 2022
$16.7M ↗
Companies contract with Zymergen for research and development to improve bio-based products; it also works with partners to develop materials they commercialize together.
10-K for FY2021, filed Mar 30, 2022
10-K for FY2021, filed Mar 30, 2022
Year endedDecember 31, 2021 2020 2019 Customer A 25 % 35 % 14 % Customer B 23 % * — % Customer C 14 % 18 % 16 % Customer D * 10 % — %…View ↗
No. It lost $361.8M in FY2021.
10-K for FY2021, filed Mar 30, 2022
−$347.6MView ↗
10-K for FY2021, filed Mar 30, 2022
−$361.8MView ↗
10-K for FY2021, filed Mar 30, 2022
−$335.9MView ↗
10-Q for Q2 FY2022, filed Aug 16, 2022
−$116.5MView ↗
8-K, filed Oct 19, 2022
BOSTON, MA and EMERYVILLE, CA – October 19, 2022 – Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell…View ↗
Grew.
Revenue grew 9% in 2 years, from $15.4M in FY2019 to $16.7M in FY2021, about 4% a year.
10-K for FY2021, filed Mar 30, 2022
Competes with Stora Enso, Georgia-Pacific, Mondi, Sabic, Arkema, Victrex, Schott, Corning, Kolon, New England Biolabs, Hongene, Tinzyme, ThermoFisher, Aldevron, TriLink, LifeMine Therapeutics, Hexagon Biomay, Strateos, HighRes Biosolutions, and Biosero
10-K for FY2021, filed Mar 30, 2022The packaging industry is innovating at different levels of the value chain to create better performing paper-based products. This includes…View ↗
Loading...
